TNF and myeloid sarcoma: Based on the ability of TNF to induce IL-6 secretion by astrocytes [28–30] and the reduction in secondary progressive disease in MS patients treated with a TNF inhibitor [31, 32], we examined the therapeutic potential of inhibiting both soluble and transmembrane TNF in the progressive EAE model.